Asset Publisher

Newsroom Events
Research

A New Broad-Spectrum Antiviral Against Neglected and Emerging Diseases

Photo: PATH global health
Date
16/01/2018
Hour
10:00
Place
Aula 10, Facultat de Medicina i Ciències de la Salut (Campus Clínic), Universitat de Barcelona
(Casanova, 143) Barcelona
Speaker
Jesús Purroy (Àvida-Biotech)

Àvida-Biotech is developing products derived from a broad-spectrum antiviral called ABT001, that has been validated in vitro with several viruses. It is worth noting that the researchers have immunized mice against dengue with an oral live attenuated vaccine, made with dengue virus attenuated with ABT001. Their aim is to develop oral, non-refrigerated vaccines and therapeutics agains viral diseases, with a focus on diseases affecting people living in low- and middle-income countries.

Scientists and administrators are invited to this meeting, conducted by Jesús Purroy, to explore the possibility of establishing further collaborations along two lines: development of applications of ABT001 as well as playing an advisory role.

Speaker

Jesús Purroy is founder and CEO of Àvida-Biotech. He is a molecular biologist with experience in both academic and industrial research. He was Scientific Director at the Barcelona Science Park, where he led a team of over 100 scientists. He has been involved in many entrepreneurial projects in health as a mentor, founder, investor and consultant.